Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

November 23, 2026

Study Completion Date

February 23, 2027

Conditions
ARDSSARS-CoV 2 Pneumonia
Interventions
OTHER

blood sample and bronchoalveolar lavage

"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."

Trial Locations (1)

13015

RECRUITING

Service Médecine Intensive Réanimation, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER